Announcements Trials
Browse Landscape

Phase

Phase 2 52Phase NA 12Phase 2/3 6Phase 4 5Phase 3 5Phase 1 3Phase EARLY_PHASE1 2Phase 1/2 1

Status

Unknown 5Completed 1

Sponsor Class

OTHER 6INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 6

Conditions

Breast Neoplasms 91Neoplasms 75Prostatic Neoplasms 54Carcinoma, Hepatocellular 53Colorectal Neoplasms 49Leukemia, Myeloid, Acute 41Stomach Neoplasms 36Carcinoma, Non-Small-Cell Lung 36Precursor Cell Lymphoblastic Leukemia-Lymphoma 34Neoplasm Metastasis 29Pancreatic Neoplasms 27Lung Neoplasms 26Rectal Neoplasms 23Multiple Myeloma 21Hematologic Neoplasms 21Head and Neck Neoplasms 20Colonic Neoplasms 20Recurrence 19Lymphoma 19Leukemia 19Polycystic Ovary Syndrome 16Liver Neoplasms 14Esophageal Neoplasms 14Brain Neoplasms 13Myelodysplastic Syndromes 12Melanoma 12Endometrial Neoplasms 12Uterine Cervical Neoplasms 11Motor Activity 11Fatigue 11

Interventions

Pemetrexed 2spartalizumab 1aflutinib 1Tyrosine Kinase Inhibitors 1Thalidomide 1Radiosurgery 1Platinum 1Immune Checkpoint Inhibitors 1Gefitinib 1Drug Therapy 1Axitinib 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2/3 × OTHER × NSCLC × Clear all
NCT03256981 2023-12-26

HALT

Institute of Cancer Research, United Kingdom

Phase 2/3 Unknown
113 enrolled
Thoracic

NSCLC

NCT06020352 2023-08-31

The Efficacy and Safety of KN046 Combined With Axitinib

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2/3 Unknown
20 enrolled
Thoracic

NSCLC

NCT05605613 2022-11-09

PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

The First Affiliated Hospital of Zhengzhou University

Phase 2/3 Unknown
150 enrolled
Thoracic

NSCLC

NCT05209256 2022-01-26

Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

The First Affiliated Hospital of Henan University of Science and Technology

Phase 2/3 Unknown
90 enrolled
Thoracic

NSCLC

NCT01769066 2016-02-23

Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC

Fudan University

Phase 2/3 Completed
117 enrolled
Thoracic

NSCLC

NCT02387086 2015-03-12

Gefitinib Combined With Thalidomide to Treat NSCLC

Shaanxi Provincial People's Hospital

Phase 2/3 Unknown
380 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡